Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium (225Ac) ancelvotide guraxetan
- Development stage
- Discontinued
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
225Ac-PNT2001 (actinium (225Ac) ancelvotide guraxetan, LY4181530) is a next-generation, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy. It consists of the alpha-emitting radioisotope actinium-225 conjugated to PSMA-62, a small-molecule PSMA inhibitor, via a novel linker technology designed to enhance cellular internalization, improve biodistribution, and reduce off-target toxicities (such as xerostomia and renal toxicity) compared to first-generation PSMA radioligands. Originally developed by Scintomics and licensed to POINT Biopharma (subsequently acquired by Eli Lilly), the drug was evaluated in the Phase I/II ACCEL trial (NCT06229366) for metastatic castration-resistant prostate cancer (mCRPC) and oligometastatic hormone-sensitive prostate cancer (OmHSPC). However, in February 2026, Eli Lilly announced the termination of its development due to efficacy concerns.
- Other names
- actinium (225Ac) ancelvotidum guraxetanumactinium Ac 225 ancelvotide guraxetanancelvotide guraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on actinium (225Ac) ancelvotide guraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium (225Ac) ancelvotide guraxetan.